Skip to main content
Top
Published in: PharmacoEconomics 9/2008

01-09-2008 | Briefing Paper

Estimating ‘Costs’ for Cost-Effectiveness Analysis

Author: Dr Alec Miners

Published in: PharmacoEconomics | Issue 9/2008

Login to get access

Abstract

Since 1999, the National Institute for Health and Clinical Excellence (NICE) Technology Appraisal Programme has been charged with producing guidance for the NHS in England and Wales on the appropriate use of new and existing healthcare programmes. Guidance is based on an assessment of a number of factors, including cost effectiveness. The identification, measurement and valuation of costs are important components of any cost-effectiveness analysis. However, working through these steps raises a number of important methodological questions. For example, how should ‘future’ resource use be estimated, and is there a need to consider all ‘future’ costs? Given that NICE produces national guidance, should national unit cost data be used to value resources or should local variations in negotiated prices be taken into account? This paper was initially prepared as a briefing paper as part of the process of updating NICE’s 2004 Guide to the Methods of Technology Appraisal for a workshop on ‘costs’. It outlines the issues that were raised in the original briefing paper and the subsequent questions that were discussed at the workshop.
Literature
1.
go back to reference National Institute for Health and Clinical Excellence. Guide to the technology appraisals process. London: NICE, 2004 [online]. Available from URL: http://www.nice.org.uk/niceMedia/pdf/TAP_Methods.pdf [Accessed 2007 Jun 4] National Institute for Health and Clinical Excellence. Guide to the technology appraisals process. London: NICE, 2004 [online]. Available from URL: http://​www.​nice.​org.​uk/​niceMedia/​pdf/​TAP_​Methods.​pdf [Accessed 2007 Jun 4]
2.
go back to reference Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004; 13 (5): 437–452PubMedCrossRef Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004; 13 (5): 437–452PubMedCrossRef
3.
go back to reference Dakin HA, Devlin NJ, Odeyemi IAO. ‘Yes’, ‘No’ or ‘Yes, but’? Multinomial modelling of NICE decision-making. Health Pol 2006; 77 (3): 352–367CrossRef Dakin HA, Devlin NJ, Odeyemi IAO. ‘Yes’, ‘No’ or ‘Yes, but’? Multinomial modelling of NICE decision-making. Health Pol 2006; 77 (3): 352–367CrossRef
4.
go back to reference Morris SN, Devlin N, Parkin D. Economic analysis in health care. Chichester: John Wiley and Sons, Ltd, 2007 Morris SN, Devlin N, Parkin D. Economic analysis in health care. Chichester: John Wiley and Sons, Ltd, 2007
5.
go back to reference Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press, 2005 Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press, 2005
6.
go back to reference Claxton K, Sculpher M, Culyer AJ. Mark versus Luke? Appropriate methods for the evaluation of public health interventions [research paper]. York: University of York, Centre for Health Economics, 2007 Nov [online]. Available from URL: http://www.york.ac.uk/inst/che/pdf/rp31.pdf [Accessed 2008 Jul 11] Claxton K, Sculpher M, Culyer AJ. Mark versus Luke? Appropriate methods for the evaluation of public health interventions [research paper]. York: University of York, Centre for Health Economics, 2007 Nov [online]. Available from URL: http://​www.​york.​ac.​uk/​inst/​che/​pdf/​rp31.​pdf [Accessed 2008 Jul 11]
7.
go back to reference Brouwer WB, van Exel NJ, Baltussen RM, et al. A dollar is a dollar is a dollar: or is it? Value Health 2006; 9 (5): 341–347PubMedCrossRef Brouwer WB, van Exel NJ, Baltussen RM, et al. A dollar is a dollar is a dollar: or is it? Value Health 2006; 9 (5): 341–347PubMedCrossRef
8.
go back to reference Johnston K, Buxton MJ, Jones DR, et al. Assessing the costs of health care technologies in clinical trials. Health Technol Assess 1999; 3 (6): 1–76PubMed Johnston K, Buxton MJ, Jones DR, et al. Assessing the costs of health care technologies in clinical trials. Health Technol Assess 1999; 3 (6): 1–76PubMed
9.
go back to reference Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness analysis in health and medicine. New York: Oxford University Press, 1996 Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness analysis in health and medicine. New York: Oxford University Press, 1996
10.
go back to reference Mushlin Al, Fintor L. Is screening for breast cancer cost-effective? Cancer 1992; 69 Suppl. 7: 1957–1962PubMedCrossRef Mushlin Al, Fintor L. Is screening for breast cancer cost-effective? Cancer 1992; 69 Suppl. 7: 1957–1962PubMedCrossRef
11.
go back to reference Johannesson M, Meltzer D, O’Conor RM. Incorporating future costs in medical cost-effectiveness analysis: implications for the cost-effectiveness of the treatment of hypertension. Med Decis Making 1997; 17: 382–389PubMedCrossRef Johannesson M, Meltzer D, O’Conor RM. Incorporating future costs in medical cost-effectiveness analysis: implications for the cost-effectiveness of the treatment of hypertension. Med Decis Making 1997; 17: 382–389PubMedCrossRef
12.
go back to reference Moskowitz M. Costs of screening for breast cancer. Radiol Clin North Am 1987; 25: 1031–1037PubMed Moskowitz M. Costs of screening for breast cancer. Radiol Clin North Am 1987; 25: 1031–1037PubMed
13.
go back to reference National Collaborating Centre for Cancer. Prostate cancer: diagnosis and treatment [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/CG58FullGuideline.pdf [Accessed 2008 May 1] National Collaborating Centre for Cancer. Prostate cancer: diagnosis and treatment [online]. Available from URL: http://​www.​nice.​org.​uk/​nicemedia/​pdf/​CG58FullGuidelin​e.​pdf [Accessed 2008 May 1]
14.
go back to reference Briggs A, Gray A. The distribution of health care costs and their statistical analysis for economic evaluation. J Health Serv Res Policy 1998; 3 (4): 233–345PubMed Briggs A, Gray A. The distribution of health care costs and their statistical analysis for economic evaluation. J Health Serv Res Policy 1998; 3 (4): 233–345PubMed
15.
go back to reference Briggs A, Gray A. Handling uncertainty in economic evaluations of healthcare interventions. BMJ 1999; 319 (7210): 635–638PubMedCrossRef Briggs A, Gray A. Handling uncertainty in economic evaluations of healthcare interventions. BMJ 1999; 319 (7210): 635–638PubMedCrossRef
16.
go back to reference Briggs A, Clark T, Wolstenholme J, et al. Missing, presumed at random: cost analysis of incomplete data. Health Econ 2003; 12 (5): 377–392PubMedCrossRef Briggs A, Clark T, Wolstenholme J, et al. Missing, presumed at random: cost analysis of incomplete data. Health Econ 2003; 12 (5): 377–392PubMedCrossRef
17.
go back to reference Drummond M, McGuire A. Economic evaluation in health care: merging theory with practice. New York: Oxford University Press, 2001 Drummond M, McGuire A. Economic evaluation in health care: merging theory with practice. New York: Oxford University Press, 2001
18.
go back to reference Raikou M, McGuire A. Estimating medical care costs under conditions of censoring. J Health Econ 2004; 23 (3): 443–470PubMedCrossRef Raikou M, McGuire A. Estimating medical care costs under conditions of censoring. J Health Econ 2004; 23 (3): 443–470PubMedCrossRef
19.
go back to reference Young T. Estimating mean total costs in the presence of censoring: a comparative assessment of methods. Pharmacoeconomics 2005; 23 (12): 1229–1242PubMedCrossRef Young T. Estimating mean total costs in the presence of censoring: a comparative assessment of methods. Pharmacoeconomics 2005; 23 (12): 1229–1242PubMedCrossRef
20.
go back to reference Calvert NW, Morgan AB, Catto JW, et al. Effectiveness and cost-effectiveness of prognostic markers in prostate cancer. Br J Cancer 2003; 88 (1): 31–35PubMedCrossRef Calvert NW, Morgan AB, Catto JW, et al. Effectiveness and cost-effectiveness of prognostic markers in prostate cancer. Br J Cancer 2003; 88 (1): 31–35PubMedCrossRef
21.
go back to reference UK Department of Health. NHS reference costs 2006–07. London: DH, 2008 Feb [online]. Available from URL: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_082571 [Accessed 2008 Mar 1] UK Department of Health. NHS reference costs 2006–07. London: DH, 2008 Feb [online]. Available from URL: http://​www.​dh.​gov.​uk/​en/​Publicationsands​tatistics/​Publications/​PublicationsPoli​cyAndGuidance/​DH_​082571 [Accessed 2008 Mar 1]
22.
go back to reference Buxton MJ, Acheson R, Caine R, et al. Costs and benefits of the heart transplant programmes at Harefield and Papworth Hospitals [research report no.2]. London: Department of Health and Social Security, 1985 Buxton MJ, Acheson R, Caine R, et al. Costs and benefits of the heart transplant programmes at Harefield and Papworth Hospitals [research report no.2]. London: Department of Health and Social Security, 1985
Metadata
Title
Estimating ‘Costs’ for Cost-Effectiveness Analysis
Author
Dr Alec Miners
Publication date
01-09-2008
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 9/2008
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200826090-00005

Other articles of this Issue 9/2008

PharmacoEconomics 9/2008 Go to the issue